Science: Biology

University Hospital Salzburg Selects IntraOp® Mobetron®

Leave a comment


Prelude®, Sightline™, Mobetron®

Image-Guided Electron Therapy

We consider Mobetron as a perfect platform for further development of our IORT program and to implement image guided 3D treatment planning.


SUNNYVALE, Calif. (PRWEB)

IntraOp Medical Corporation announced today that University Hospital Salzburg (SALK) Austria has purchased the IntraOp’s third generation Mobetron and advanced treatment planning software, to pursue implementing Image Guided Electron Therapy (IGET) for intraoperative radiation therapy (IORT) clinically.

The Paracelsus Medical University Hospital Salzburg has been a pioneering thought leader in IORT for more than 20 years. Professor Felix Sedlmayer, head of radiation oncology and president of the International Society of IORT (ISIORT) said: “We consider Mobetron as a perfect platform for further development of our IORT program and to implement image guided 3D treatment planning.”

Prof. Sedlmayer is the Principal Investigator in the ongoing HIOB trial (Hypofractionated Whole-Breast Irradiation preceded by Intra-Operative Radiotherapy with Electrons as anticipated Boost). HIOB is the largest prospective multi-institutional trial studying the benefits of electron IORT in the treatment of breast cancer.

“We are delighted to be partnering with Professor Sedlmayer and the team at University Hospital Salzburg and providing the most advanced IORT technology available today,” said Derek T. DeScioli, Chief Executive Officer of IntraOp Medical Corporation. “Their institution has been a pioneer in IORT from the beginning, and we look forward to working with them to advance the research and technology to the next level of sophistication.”

IntraOp will be providing to University Hospital Salzburg its third generation Mobetron technology including automatic soft docking, Prelude® IORT Management system and Radiance® 3D treatment planning as well high density radiotranslucent applicators compatible with Image Guided Electron Therapy.

About IntraOp Medical Corporation

IntraOp® is the leading innovator of electron radiation devices for treating cancer as an adjunct to invasive surgical procedures. As the developer and manufacturer of Mobetron®, IntraOp pioneered the world’s first portable, self-shielded LINAC used for electron-based Intraoperative Radiation Therapy (IORT). Over 20,000 patients in 16 countries have benefited from Mobetron IORT. Based in Sunnyvale, California, IntraOp is a cancer care company uniting radiation and surgical oncology in the fight against cancer. For more information, please visit https://intraop.com.

Product photography available upon request.

Share article on social media or email:

Technology: Computer

Damo Consulting Releases 2019 Mid-Year “WITCH Report” Of Healthcare IT Consulting Firms

Leave a comment



CHICAGO (PRWEB)

Damo Consulting, a leading digital transformation and growth strategy consultancy for healthcare enterprises and technology firms, today announced the release of its mid-year WITCH Report, which provides a market landscape view of the major global technology consulting firms in healthcare and life sciences. The findings indicate declining growth in the healthcare business of the major global technology firms, but more promising growth within life sciences areas.

The one-of-a-kind WITCH Report, which has been published since 2015, includes a comprehensive review of the financial and market performance of 12 global technology consulting firms in healthcare and life sciences. It provides a detailed review of market performance metrics, insights, and activities of Wipro, Infosys, TCS, Cognizant Technology Solutions, and HCL (WITCH), along with other industry leaders. Information covered in the WITCH Report includes financial performance, M&A activities, customer wins, partnerships, new product initiatives, and leadership announcements.

“Our mid-year review of 12 global technology consulting firms indicates declining growth rates in the past two quarters due to a variety of factors for most of the firms. Large-scale M&A in the health insurance industry, notably CVS-Aetna and Cigna-Express Scripts, has created pricing pressures and related challenges for some firms,” said Paddy Padmanabhan, CEO of Damo Consulting and author of The Big Unlock: Harnessing Data and Growing Digital Businesses in a Value-Based Era.

“In the payer space, several clients of technology providers are in-sourcing their operations which leads to further pressures on topline growth for firms with large exposure to this sector. At the same time, cost pressures faced by clients have resulted in demand slowdown for the short term. The life sciences segment seems to have done better as compared to the healthcare segment for most firms, with one firm being an exception. In terms of deal wins, publicly announced transactions were few.”

A challenge for many of the firms covered in the report is increased levels of H1B visa rejections which create pressures on hiring and margins for onsite client engagements. The ongoing opioid lawsuits could impact overall IT spend by Pharma companies facing monetary penalties, which in turn will impact consulting firms with exposure to these companies.

Compiled from publicly available information, the WITCH Report is a complimentary report that provides the most comprehensive overview of the healthcare market performance of the major global technology consulting firms. In addition to the WITCH companies, the report covers Accenture, Atos, Capgemini, DXC Technology, IBM, and NTT Data, Optum, and Deloitte.

To download the report, visit: https://www.damoconsulting.net/the-witch-report-2019-mid-year-review/

About Damo Consulting

Damo Consulting is a growth strategy and digital transformation advisory firm that works with healthcare enterprises and global technology companies. We help develop and implement digital transformation strategies and enable market growth strategies. We specialize in thought leadership led brand transformation and actionable healthcare market intelligence.

For media inquiries, write to us at info@damoconsulting.net

Share article on social media or email:

Technology: Electronics

CHASM Advanced Materials Partners with Screentec to Offer Transparent Printed Electronics Throughout Europe

Leave a comment


CHASM Advanced Materials

CHASM Advanced Materials

“When security or safety of passengers is at risk or patients’ lives are in the balance, the optoelectronic performance and environmental stability of CHASM’s AgeNT™ provides Screentec an ideal platform for electronics that work reliably the first time, every time,” said David Arthur, CEO of CHASM.


CANTON, Mass. (PRWEB)

CHASM Advanced Materials, the exclusive developer and manufacturer of carbon nanotube (CNT) hybrid transparent conductive films, announced today that it has entered into a partnership with Screentec, a leader in the printed electronics field. This partnership agreement via CHASM’s Preferred Integration Partner Program will draw on the strengths of Screentec’s skilled team of printed electronics experts and CHASM’s boundary pushing CNT Hybrid platform, AgeNT™.

As technology accelerates, product designers and engineers require new, advanced materials that enable their dreams to become reality. With AgeNT transparent conductive films available exclusively from CHASM, product designers and engineers can innovate next generation products unbounded by traditional electronics. Applications of AgeNT include transparent heaters for automotive headlights as well as resistive touch screens for appliances, both of which Screentec will be demonstrating live in Stand E119 at the Alihankinta Subcontracting Fair in Finland September 24-26, 2019.

“Our customers value the high-quality and innovative solutions we develop for user interfaces used in demanding environments, disposable medical electrodes and sensors,” said Mikko Paakkolanvaara, Chief Technology Officer at Screentec. “Adding CHASM’s AgeNT platform to our capabilities expands our resources and enables us to successfully develop new and innovative applications for more clients across industries such as healthcare, automotive and heavy industry.”

“We are delighted to welcome Screentec into our Preferred Integration Partner Program,” said David Arthur, CEO of CHASM. “Screentec’s unique expertise in developing and manufacturing flexible printed electronics in which wear resistance and reliability are a must makes them a distinct addition to our PIP program. When security or safety of passengers is at risk or patients’ lives are in the balance, the optoelectronic performance and environmental stability of CHASM’s AgeNT provides Screentec an ideal platform for electronics that work reliably the first time, every time.”

Membership in the CHASM PIP is offered exclusively to companies not just having an established customer base for flexible printed electronics but also those demonstrating leading expertise at integrating flexible printed electronics into finished product or electronic assemblies. PIP member companies represent the “go-to” companies in the industry, offering their customers extensive integration capabilities and consultative expertise on the latest innovations.

About CHASM Advanced Materials

CHASM Advanced Materials is revolutionizing design and fabrication of printed electronics and energy storage devices through exclusive development and manufacture of CNT hybrid transparent conductive films and CNT hybrid electrode materials. The company’s line of AgeNT transparent conductive films is flexible and formable with low pattering costs and low sheet resistance at high transparency. Leading companies across multiple industries have successfully launched next generation innovations using transparent circuits, heaters, antennas, and films as well as advanced CNT inks and carbon nanotubes (CNTs) only available from CHASM. For more information, visit http://www.chasmtek.com or follow us: @CHASMAdvanced, LinkedIn, Instagram, and Facebook.

For more information on becoming a CHASM Preferred Integration Partner, click here, contact sales@chasmtek.com or call +1.781.821.0443.

About Screentec

Screentec is a leading contract manufacturer in the field of printed electronics in demanding environments where devices must work the first time, every time. The company provides innovative and cutting-edge solutions in the field of user interfaces, disposable medical electrodes and sensor applications serving international customers in the medical, automotive and transport industries, among others. Screentec’s customers have come to rely on the company’s flexible production methods to ensure their product’s success. Learn more on our website at http://www.screentec.com or connect with us on LinkedIn.

Share article on social media or email:



Society: Disabled Issues / Disabilities

Mental Health America Releases its Annual State of Mental Health Report; Shows Adults, Children in Crisis

Leave a comment


News Image

“We must continue to improve access to care and treatments, and we need to put a premium on early identification and early intervention for everyone with mental health concerns. We must address these mental health concerns before crisis and tragedy strikes—before Stage 4.”


ALEXANDRIA, Va. (PRWEB)

For the 6th year in a row, Mental Health America (MHA) released its annual State of Mental Health Report, which ranks all 50 states and the District of Columbia based on several mental health and access measures. This year, Pennsylvania came out on top overall with Nevada coming in 51st. The report also takes a look back on the trends of the last 6 years and shows that many are still not receiving the treatment they need.

Most alarmingly, the data show that the mental health of our youth is getting worse, not better. Major depression in youth has increased 4.35 percent over the last 6 years – meaning over 2 million youth have severe depression. Shockingly, almost 60 percent of youth with major depression do not receive any mental health treatment.

“Sadly, our report shows that our children continue to be in crisis,” said Paul Gionfriddo, president and CEO, MHA. “Despite mental health being something that more and more people are talking about – far too many young people are still suffering. It is imperative that we prioritize mental health for children and adolescents so that we can avoid crisis and so they can live healthy and productive lives.”

The data show that children are not the only ones in trouble. Adults are struggling as well:


  • Over 45 million Americans – almost 20% – are experiencing a mental illness;

  • Over 10.3 million adults have serious thoughts of suicide in the United States – an increase of nearly 450,000 people from last year’s data set; and

  • 57 percent of adults with a mental illness receive no treatment.

In developing the report, MHA looked at 15 different measures to determine the rankings. MHA hopes to provide a snapshot of mental health status among youth and adults for policy and program planning, analysis, and evaluation; to track changes in prevalence of mental health issues and access to mental health care; to understand how changes in national data reflect the impact of legislation and policies; and to increase the dialogues and improve outcomes for individuals and families with mental health needs.

While much of the state of our mental health care continues to be broken, there are glimmers of hope. The data show that the rate of substance use disorders (SUD) in adults and in youth ages 12-17 has decreased. Public health and prevention efforts to limit the availability of drugs appear to have been successful in reducing the prevalence of SUD among children and adults in the U.S. That said, alcohol continues to be the most commonly used substance among adolescents and adults, with nearly three-quarters of people over the age of 12 with a SUD in the last year having an alcohol use disorder.

“While there are some improvements, it is clear we are not doing enough,” concluded Gionfriddo. “We must continue to improve access to care and treatments, and we need to put a premium on early identification and early intervention for everyone with mental health concerns. We must address these mental health concerns before crisis and tragedy strikes—before Stage 4.”

Mental Health America (MHA) – founded in 1909 – is the nation’s leading community-based nonprofit dedicated to addressing the needs of those living with mental illness and to promoting the overall mental health of all Americans. Our work is driven by our commitment to promote mental health as a critical part of overall wellness, including prevention services for all; early identification and intervention for those at risk; integrated care, services, and supports for those who need it; with recovery as the goal. Learn more at http://www.mhanational.org

Share article on social media or email:

health and fitness

Frame Park is the First National Demonstration Site to be Awarded Four NDS Designations

Leave a comment


“We make a concerted effort to find ways to better respond to the community’s needs, especially when it comes to health and wellness,” according to City of Waukesha Parks, Recreation & Forestry (WPRF) Director Ron Grall.


WAUKESHA, Wis. (PRWEB)

Frame Park in Waukesha, Wisconsin is the first National Demonstration Site to be awarded four designations. This signature city park will allow the community to enjoy an outdoor adult fitness space and an inclusive playground that offers the six elements of play in a naturalized setting.

“We make a concerted effort to find ways to better respond to the community’s needs, especially when it comes to health and wellness,” according to City of Waukesha Parks, Recreation & Forestry (WPRF) Director Ron Grall. When proposed with the idea of becoming a National Demonstration Site, they gladly accepted the challenge. Out of the 30 playgrounds in the park system, they chose Frame Park to be the site for this project, as it is heavily-used and recognizable by the community and regional area. As the department reviewed the NDS designation options, they found it difficult to leave anything on the table as they each can offer unique benefits to the community in a variety of ways. The team reached out to Minnesota Wisconsin Playgrounds of Minneapolis, MN, to make their dreams come true. As a team trained in National Demonstration Site design, Minnesota Wisconsin was thrilled to be a part of the project.

Once extensive equipment plans were formalized with the NDS goals in mind, decisions needed to be made regarding the disposition of their existing playground equipment. Waukesha identified a way to bring the “joy of play” to communities in need by partnering with the Kids Around the World (KAW) program. KAW “harvested” and refurbished the old playground equipment with the end goal of relocating to a poverty-stricken area of the world. Following the playground “harvest”, WPRF held a “community build” September 3-5 with 182 community volunteers participating to bring their new space to life! The new play and fitness space also features a fully accessible poured-in-place rubber surfacing that exceeds current “fall factor” standards.

Grand Opening is scheduled for September 18, 2019 from 5-7 PM (CDT). Each National Demonstration Site designation area will be hosting individual activities, NatureGrounds will have a tree planting, DJ entertainment, community picnic, and tree identification; Outdoor Adult Fitness will have personal trainer sessions demonstrating safety tips and how to use the equipment; Inclusion and Play On! playground will have game sessions utilizing activities found in 2Play Together and Play On! to show families and the community how they can best utilize the play space. Waukesha plans to continue to program the space by adding the activity books to their public library for community use and will host a personal trainer session once a month from September to November.

Frame Park Playground-Fitness area is recognized as a project of excellence meeting the National Demonstration Site design criteria for inclusion, outdoor adult fitness, nature integration, and youth physical activity, and honored for their outstanding commitment and leadership to providing such a high-quality play and recreation destination.

To continue to celebrate WPRF’s commitment to advancing play and recreation through best practices, the department will receive a certificate of recognition, become a part of a network of potential research sites, and will be promoted actively to other communities wishing to create recreation spaces using design and/or programming. To locate the new site, check out http://www.playcore.com/nds/map.

About PlayCore:

PlayCore is a purpose driven Company committed to building stronger communities around the world by advancing play and recreation. The company infuses scholarly learning, through its Center for Outreach, Research, and Education, into its comprehensive family of brands. PlayCore combines best-in-class educational programming with the most comprehensive portfolio of play and recreation products and services to create tailored solutions that match the unique needs of each community served. Learn more at http://www.playcore.com.

Share article on social media or email:

Industry: Healthcare

Navigating Cancer, the Leader in Oncology Patient Relationship Management, Receives $26 Million in Oversubscribed New Funding

Leave a comment



SEATTLE (PRWEB)

Navigating Cancer (NC), the leader in enabling personalized cancer care with its comprehensive oncology patient relationship management solution, announced today that it has received $26 million in Series D growth equity funding in an over-subscribed round led by the Merck Global Health Innovation Fund (GHIF) and TT Capital Partners (TTCP). The company’s end-to-end software platform, adopted by more than 1,700 cancer care providers domestically, uniquely connects providers and their patients throughout the care cycle.

Other investors in the round include BrightEdge, the American Cancer Society’s newly formed philanthropic venture fund; LabCorp®; ORIX Growth Capital; and Rustic Canyon Partners.

The funding will enable NC to accelerate innovation of its Patient Relationship Management (PRM) platform, including delivery of a more robust mobile experience for oncology patients and the development of NC’s AI-based population care capabilities. With NC’s platform, oncology practices are able to increase patient engagement, create a more responsive experience for cancer patients, and ultimately improve overall cancer care.

Forty Percent Growth Predicted in 2019

For 2019, Navigating Cancer is on pace to grow its oncology customer base by 40 percent. Accelerating adoption of NC’s unique platform is enabling more practices to succeed in delivering value-based care, a model that pays hospitals and physicians based on patient outcomes as opposed to fixed fees based on the service provided.

Navigating Cancer’s PRM platform helps providers manage patient interactions, improve the patient experience, and deliver value-based care more effectively – increasing the flow of communications between in-office visits, which, in turn, boosts patient engagement in their own care. NC’s platform also helps providers contain escalating costs. According to a study published in the Journal of Oncology Practice, two community cancer centers utilizing NC’s PRM platform generated significant cost savings due to better symptom management, while reducing emergency room visits by seven percent.

“This investment from these leading healthcare organizations really affirms the work that Navigating Cancer is doing to improve patient care and the success we’re seeing in helping oncology providers make the shift to value,” said Bill Bunker, the CEO of Navigating Cancer. “I’m excited about the innovations we’re making in areas like patient-reported outcomes and population care and the potential they have to further improve patient outcomes and satisfaction.”

“Oncologists must care for patients in an extremely complex regulatory and reimbursement environment, while managing a rapidly expanding number of therapy choices and effects across indications,” said David M. Rubin, Ph.D., Managing Director of Merck GHIF. “We’re delighted to continue our investment in this comprehensive patient care platform.”

Specifically, patients using the PRM platform can send messages to their doctor, receive reminders to take their medications, and report symptoms via a mobile app. Care providers, meanwhile, can triage patient needs; assess and manage symptoms and side effects; and streamline communications and care coordination for quicker responses.

Going forward, innovation in the PRM platform will incorporate artificial intelligence to support the assessment of patients at risk for various issues and identify proactive interventions to help improve care.

“More and more oncology practices are picking up the NC oncology platform because it’s a superb example of the heightened effectiveness created by leveraging 21st century technology in the practice of medicine,” said Bob Crutchfield, managing director of BrightEdge, the philanthropic impact fund of the American Cancer Society.

“As the dynamics of how providers, patients, and caregivers interact with one another continue to change in healthcare, Navigating Cancer’s platform represents a powerful example of technology enhancing the delivery of care and improving the overall healthcare experience,” said Tim Scallen, Principal at TT Capital Partners. “We look forward to collaborating with the management team to further extend Navigating Cancer’s platform reach and enhance the benefits it delivers to all cancer patients and providers.”

About Navigating Cancer

Navigating Cancer is the leading Patient Relationship Management technology and solutions company focused on improving the patient experience, delivering more effective care management and enabling oncology care innovation. With over 1,700 providers adopting the Navigating Care platform, it is the most broadly deployed patient management solution in oncology. The company’s products combine clinical workflows, oncology content and data insights to empower personalized care for cancer patients inside and outside of the clinic. For more information, please visit http://www.navigatingcancer.com or follow Navigating Cancer on Twitter @navcancer.

About TT Capital Partners

TT Capital Partners (TTCP) is a healthcare investor, collaborating with healthcare technology and services companies that have the potential to become market leaders. Leveraging the insights garnered from a unique knowledge-based platform, TTCP has invested in some of the most innovative, high-growth healthcare businesses. TTCP is part of the TripleTree healthcare merchant bank. For more information, visit TTCapitalPartners.com.

About BrightEdge

BrightEdge is the American Cancer Society’s donor-funded, philanthropic impact fund. The fund is led by a board comprised of the Society’s leaders and a management team with expertise in investment and venture capital. BrightEdge operates under a charitable fund model that invests in for-profit companies developing novel cancer-focused therapies and technologies. The fund relies on the expertise of the Society’s medical and science professionals to evaluate the mission value of its investments. The fund’s goal is to accelerate delivery of promising cancer-related solutions through capital investment, market awareness and a shared commitment to eradicate cancer. https://brightedgefund.org/.

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenues of more than $11 billion in 2018. To learn more about LabCorp, visit http://www.LabCorp.com, and to learn more about Covance Drug Development, visit http://www.Covance.com.

Business: Insurance

What are the Main Benefits of Crash Avoidance Technology

Leave a comment


News Image

“Investing in crash-avoidance technology is money well-spent. Nothing is more important than your life,” said Russell Rabichev, Marketing Director of Internet Marketing Company.


LOS ANGELES (PRWEB)

Compare-autoinsurance.org has released a new blog post that presents the benefits of crash-avoidance technology and how it can help drivers lower car insurance premiums.

For more info and free auto insurance quotes, visit https://compare-autoinsurance.org/how-crash-avoidance-technology-works-and-its-benefits/.

A high number of cars translates into a high likelihood of being involved in an accident. To decrease the odds, more and more cars are equipped with performant sensors and cameras. Crash-avoidance technology informs the driver when a car, obstacle or pedestrian gets too close. This technology will reduce the number of accidents and will save lives.

The most popular crash-avoidance systems include:

  • Frontal collision prevention. These systems are complex, comprising several sensors, radars and cameras (including night-vision cameras) and will detect nearby cars and obstacles. Some systems will automatically brake in order to prevent a collision.

  • Lane departure warning is also an extremely useful system. If the driver passes the lane lines, he will receive audio warnings. Just like in the case of frontal collision prevention, the system may take over control and guide the car to the correct lane.

  • Blind spot detectors are probably some of the most popular systems. Sensors will detect cars placed in the blind spots and will emit various luminous signals (usually on dashboard, rear camera or mirror).

  • Adaptive cruise control will measure the distance between the driver’s car and the car in front and calculate its speed. In order to maintain a safe driving distance, the system will adjust the speed of the car.


For more information and free online quotes, please visit http://compare-autoinsurance.org.

Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

Share article on social media or email:

Business: Executives

Morphisec Appoints Eric Dougherty as Chief Revenue Officer

Leave a comment


Morphisec

Morphisec is uniquely positioned to capitalize on this change in enterprise security strategies, and Eric’s extensive experience working with growth companies, as well as his track record in building successful global sales teams, makes him an ideal appointment to our leadership team.


BE’ER SHEVA, Israel and BOSTON (PRWEB)

Morphisec, the leader in Moving Target Defense, today announced it has appointed Eric Dougherty to Chief Revenue Officer (CRO). In this role, Dougherty will lead all customer acquisition, expansion and retention efforts for the company as it accelerates its growth in global markets. Morphisec has doubled the global install base of its Unified Threat Prevention platform in just over eight months to more than four million endpoints as demand skyrockets for its advanced threat protection as the ideal companion to Microsoft’s built-in Windows Defender Antivirus (AV) in more efficient enterprise security stacks.

“We’re excited to have Eric join our team as a paradigm shift is occurring in the cybersecurity market where enterprises are moving to a prevention-first model against advanced attacks as the limitations and burdens of EDR solutions becomes more apparent,” said Ronen Yehoshua, Morphisec’s CEO. “Morphisec is uniquely positioned to capitalize on this change in enterprise security strategies, and Eric’s extensive experience working with growth companies, as well as his track record in building successful global sales teams, makes him an ideal appointment to our leadership team.”

Dougherty has over two decades of experience working with growth companies in the cybersecurity, data protection, and enterprise infrastructure markets. He most recently served as VP of Americas Sales for EnterpriseDB. Prior to that, he was the SVP of worldwide sales for Unitrends. Within that role, Dougherty built the sales and channel strategy for Unitrends that resulted in a 400% growth and hitting a $100M run rate in less than four years. During his previous stints at Rapid7 and Acronis, Dougherty built go-to-market channel strategies and sales teams that led to partner expansion, customer wins, and sales growth. Dougherty also spent more than six years at Axis Communications, where his sales success as General Manager for the Americas contributed to a successful IPO in 2000.

“As enterprises move to Windows 10 they are realizing the time has come to step away from legacy antivirus tools, as well as the cost and time burden of EDR solutions,” added Dougherty. “Morphisec is reaping the benefits of the enterprise adoption of Windows Defender AV as organizations of all sizes divest themselves from redundant tools and reallocate budgets to their biggest current need — advanced threat protection. I look forward to expanding Morphisec’s sales team to meet this global demand and assisting our customers with implementing preventative endpoint security within a simpler operational environment that improves their ROI.”

About Morphisec

Morphisec delivers an entirely new level of innovation with its Moving Target Defense-powered Unified Threat Prevention Platform – placing defenders in a prevent-first posture against the most advanced threats to the enterprise, including APTs, zero-days, ransomware, evasive fileless attacks and web-borne exploits. Morphisec provides a crucial, small-footprint memory-defense layer that easily deploys into a company’s existing security infrastructure to form a simple, highly effective, cost-efficient prevention stack that is truly disruptive to today’s existing cybersecurity model.

Share article on social media or email:

Health

VISTAAR Announces Addition of “ADVISORY Playbooks” to it’s Regulatory & Clinical Intelligence Platform

Leave a comment


VISTAAR-Regulatory-Clinical-Intelligence

VISTAAR

Access Regulatory Guidance Documents with One Click


PRINCETON, N.J. (PRWEB)

VISTAAR released ADVISORY Playbooks to help small and mid-level companies who need advisory either as a primary strategy or as re-assurance / 2nd opinion to their internal strategies they formed for developing or launching new products or expanding to new countries.

Lot of users when going into new markets, or planning to change their product elements and want to know the impact, introducing new product or to support their R&D teams, have ideas and thoughts but may not have a question clearly framed. VISTAAR while driving initial probing questions, you can give your needs or plans and VISTAAR than by leveraging its AI engine provides you a Regulatory strategy on what is needed, options, country requirements, forms/checklists, what other companies are doing in that scenario, what other products have those situations or parameters and more.

When someone cannot afford a senior consultant or need an initial pathway, these Playbooks can drive that process by significantly reducing the time and cost required compared to analyzing all the documents and information manually.

Try for a month FREE to test it for yourself. VISTAAR’s AI enabled Intelligence helps navigate today’s complex product development and regulatory landscape Better, Faster and Cheaper than any other regulatory and clinical intelligence platform. Visit http://www.vistaar.ai

Share article on social media or email:

Science: Biology

Study indicates early infusion of mononuclear cells could aid in recovery from stroke

Leave a comment


https://www.prweb.com/

Lead investigator on the study, Sean Savitz, M.D.


DURHAM, N.C. (PRWEB)

Results of a clinical trial published today in STEM CELLS are the first to document the safety and feasibility of the early administration of bone marrow cells to treat acute ischemic stroke patients. The information provided by the study could aid in developing new cellular therapies for this most common form of stroke — caused by a blocked artery — which affects over 13 million people each year, according to the World Health Organization.

The study in STEM CELLS is a follow up to the initial report on the first 10 patients in the trial, published in the Annals of Neurology in 2011. The STEM CELLS paper represents the total group of 25 patients.

Sean Savitz, M.D., director of the Institute for Stroke and Cerebrovascular Disease and professor of neurology at McGovern Medical School at UTHealth Houston, was lead investigator on the study. “Having found no clear evidence of harm to the initial 10 patients,” he said, “we broadened the inclusion criteria and enrolled additional patients. Our choice of cell type — bone marrow mononuclear cells (BM MNCs) – dose (10 million cells/kg), timing; route of administration; and the autologous approach was based on, and is in line with, growing evidence from animal stroke models and clinical evidence for possible treatment effects in our traumatic brain injury studies and other diseases.”

BM MNCs are attractive in regenerative medicine studies because they can be rapidly isolated; are enriched with hematopoietic, mesenchymal and endothelial progenitor cells; and permit autologous applications. Preclinical studies consistently indicate that MNCs improve outcome when administered within 72 hours of stroke onset and at least one clinical trial has shown they are not effective beyond seven days, the researchers said.

The regenerative potential of BM-derived MNCs is attributed to various mechanisms that impact stroke recovery. The cells migrate to the site of injury, release cytokines and other trophic factors, decrease proinflammatory and upregulate anti-inflammatory pathways, among other things. They also are easily amenable to autologous infusion, eliminating the need for immunosuppressive drugs.

“In contrast to the generation of autologous mesenchymal stem cells, another promising cell therapy,” added Dr. Savitz, “MNCs do not require passage in culture, which allows for testing in the early post-stroke time window.”

Each patient in the Savitz team’s study received an intravenous dose of their own BM MNCs within 72 hours after onset of their stroke. They were then followed for one year after treatment and the results compared to a control group of 185 acute ischemic stroke patients who received conventional treatment only. No definite severe adverse events related to the procedures were seen in any of the 25 patients, the research showed.

“In the light of our findings,” said Dr. Savitz, “we believe that MNCs pose no additional harm in ischemic stroke patients when given during the acute phase, doses up to 10 million cells/kg are tolerated and it is feasible to perform a BM harvest and re-infusion of MNCs for a wide range of stroke patients. Well-designed random clinical trials are needed to further assess safety and efficacy of this novel approach to enhance stroke recovery.”

“New options to treat Ischemic stroke are desperately needed,” said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS. “This important clinical trial provides solid safety and feasibility data on which later trials can be built, using the patient’s own bone marrow stem/progenitor cells to potentially enhance recovery after ischemic stroke.”

The full article, “Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial,” can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/stem.3080.

About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS® (http://www.StemCells.com) is the world’s first journal devoted to this fast paced field of research. THE ONCOLOGIST® (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE® (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company’s website can be accessed at http://www.wiley.com.

Share article on social media or email:

Press Release News Wire Service